244 related articles for article (PubMed ID: 25581877)
1. A 2013 European survey of clinical practice patterns in the management of Graves' disease.
Bartalena L; Burch HB; Burman KD; Kahaly GJ
Clin Endocrinol (Oxf); 2016 Jan; 84(1):115-20. PubMed ID: 25581877
[TBL] [Abstract][Full Text] [Related]
2. A SURVEY OF CLINICAL PRACTICE PATTERNS IN MANAGEMENT OF GRAVES DISEASE IN THE MIDDLE EAST AND NORTH AFRICA.
Beshyah SA; Khalil AB; Sherif IH; Benbarka MM; Raza SA; Hussein W; Alzahrani AS; Chadli A
Endocr Pract; 2017 Mar; 23(3):299-308. PubMed ID: 27967219
[TBL] [Abstract][Full Text] [Related]
3. 2021 Asia-Pacific Graves' Disease Consortium Survey of Clinical Practice Patterns in the Management of Graves' Disease.
Parameswaran R; de Jong MC; Kit JLW; Sek K; Nam TQ; Thang TV; Khue NT; Aye TT; Tun PM; Cole T; Miller JA; Villa M; Khiewvan B; Sirinvaravong S; Sin YL; Muhammad R; Jap TS; Agrawal A; Rajput R; Fernando R; Sumanatilleke M; Suastika K; Shong YK; Lang B; Bartalena L; Yang SP;
Endocrine; 2023 Jan; 79(1):135-142. PubMed ID: 36129592
[TBL] [Abstract][Full Text] [Related]
4. The management of Graves' disease in New Zealand 2014.
Cox SC; Tamatea JA; Conaglen JV; Elston MS
N Z Med J; 2016 Jun; 129(1436):10-24. PubMed ID: 27355225
[TBL] [Abstract][Full Text] [Related]
5. Comparison of single daily dose of methimazole and propylthiouracil in the treatment of Graves' hyperthyroidism.
He CT; Hsieh AT; Pei D; Hung YJ; Wu LY; Yang TC; Lian WC; Huang WS; Kuo SW
Clin Endocrinol (Oxf); 2004 Jun; 60(6):676-81. PubMed ID: 15163329
[TBL] [Abstract][Full Text] [Related]
6. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease.
Rittmaster RS; Zwicker H; Abbott EC; Douglas R; Givner ML; Gupta MK; Lehmann L; Reddy S; Salisbury SR; Shlossberg AH; Tan MH; York SE
J Clin Endocrinol Metab; 1996 Sep; 81(9):3283-8. PubMed ID: 8784084
[TBL] [Abstract][Full Text] [Related]
7. Hypothyroidism during antithyroid drug treatment with methimazole is a favorable prognostic indicator in patients with Graves' disease.
Choo YK; Yoo WS; Kim DW; Chung HK
Thyroid; 2010 Sep; 20(9):949-54. PubMed ID: 20629556
[TBL] [Abstract][Full Text] [Related]
8. Differences and similarities in the diagnosis and treatment of Graves' disease in Europe, Japan, and the United States.
Wartofsky L; Glinoer D; Solomon B; Nagataki S; Lagasse R; Nagayama Y; Izumi M
Thyroid; 1991; 1(2):129-35. PubMed ID: 1688014
[TBL] [Abstract][Full Text] [Related]
9. [Evolution of diagnostic and therapeutic criteria in Graves' disease in Spain. Comparison of the results of 2 surveys in 1987 and 1995].
Escobar Jiménez F; Luna López V; Fernández Soto ML; Quezada Charneco M; Glinoer D
Med Clin (Barc); 1998 Sep; 111(6):205-10. PubMed ID: 9789225
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and Management of Graves' Disease in Thailand: A Survey of Current Practice.
Sriphrapradang C
J Thyroid Res; 2020; 2020():8175712. PubMed ID: 32454522
[TBL] [Abstract][Full Text] [Related]
11. A 2011 survey of clinical practice patterns in the management of Graves' disease.
Burch HB; Burman KD; Cooper DS
J Clin Endocrinol Metab; 2012 Dec; 97(12):4549-58. PubMed ID: 23043191
[TBL] [Abstract][Full Text] [Related]
12. [Graves' Disease].
Allelein S; Schott M
Dtsch Med Wochenschr; 2021 Oct; 146(20):1337-1343. PubMed ID: 34644794
[TBL] [Abstract][Full Text] [Related]
13. Graves' disease in two pregnancies complicated by fetal goitrous hypothyroidism: successful in utero treatment with levothyroxine.
Bliddal S; Rasmussen ÅK; Sundberg K; Brocks V; Skovbo P; Feldt-Rasmussen U
Thyroid; 2011 Jan; 21(1):75-81. PubMed ID: 21162688
[TBL] [Abstract][Full Text] [Related]
14. Persistent increase in bone turnover in Graves' patients with subclinical hyperthyroidism.
Kumeda Y; Inaba M; Tahara H; Kurioka Y; Ishikawa T; Morii H; Nishizawa Y
J Clin Endocrinol Metab; 2000 Nov; 85(11):4157-61. PubMed ID: 11095447
[TBL] [Abstract][Full Text] [Related]
15. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
[TBL] [Abstract][Full Text] [Related]
16. Remission of Graves' hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment.
Takasu N; Yamashiro K; Komiya I; Ochi Y; Sato Y; Nagata A
Thyroid; 2000 Oct; 10(10):891-6. PubMed ID: 11081255
[TBL] [Abstract][Full Text] [Related]
17. Continued suppression of serum TSH level may be attributed to TSH receptor antibody activity as well as the severity of thyrotoxicosis and the time to recovery of thyroid hormone in treated euthyroid Graves' patients.
Chung YJ; Lee BW; Kim JY; Jung JH; Min YK; Lee MS; Lee MK; Kim KW; Chung JH
Thyroid; 2006 Dec; 16(12):1251-7. PubMed ID: 17199435
[TBL] [Abstract][Full Text] [Related]
18. Thyrotropin Receptor Antibody Levels at Diagnosis and After Thionamide Course Predict Graves' Disease Relapse.
Tun NN; Beckett G; Zammitt NN; Strachan MW; Seckl JR; Gibb FW
Thyroid; 2016 Aug; 26(8):1004-9. PubMed ID: 27266892
[TBL] [Abstract][Full Text] [Related]
19. TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study.
Laurberg P; Wallin G; Tallstedt L; Abraham-Nordling M; Lundell G; Tørring O
Eur J Endocrinol; 2008 Jan; 158(1):69-75. PubMed ID: 18166819
[TBL] [Abstract][Full Text] [Related]
20. Management of Graves Thyroidal and Extrathyroidal Disease: An Update.
Kahaly GJ
J Clin Endocrinol Metab; 2020 Dec; 105(12):3704-20. PubMed ID: 32929476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
